Phaseline

Companies › Qifeng Zhang

Qifeng Zhang: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BBD-1 Multi-target Immune Enhancement Targeting Agent
Multi-target immune enhancement
–Phase 2Allergic Reaction (IgA) VasculitisAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07595367BBD-1 Multi-target Immune Enhancement Targeting AgentPhase 2Allergic Reaction (IgA) VasculitisImmunologyAug 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Topadur Pharma Leadingtac Pharmaceutical (Shaoxing) Agomab Spain S.L.U.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.